The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Ben WatkinsDuring the 2021 TCT Meetings Digital Experience, the GvHD Hub spoke to Ben Watkins, Emory University, Atlanta, US. We asked, How can Day 100 transcriptomics help to predict development of chronic GvHD?
How can Day 100 transcriptomics help to predict development of chronic GvHD?
Watkins discusses a model analyzing CD4 T-cell transcriptomics at Day 100 in patients who develop de novo chronic GvHD versus patients displaying operational immune tolerance. Day 100 represented the optimal timepoint to study, as this is often the inflection point between acute and chronic GvHD.